Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

Clinical trial NCT04921527 · RECRUITING

Trial details

NCT number: NCT04921527
Sponsor: Chipscreen Biosciences, Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Ovarian Cancer Relapsed or Refractory Chiauranib Paclitaxel

Start date: 2021-12-20
Primary completion: 2024-12-31
Enrollment: 454

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.